

#56888

Date: July 16, 2025

## Subject: NXTC1 Options - Expiration Pricing Consideration

NXTC1 (adjusted NextCure, Inc. options) will be subject to special pricing consideration in expiration processing on July 18, 2025. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of NXTC1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

## <u>NXTC1</u>

NXTC1 options are adjusted NextCure, Inc. options, adjusted July 14, 2025 (see OCC Information Memo #56852). The deliverable of NXTC1 options is:

NEW DELIVERABLE PER CONTRACT: 1) 8 NextCure, Inc. (NXTC) Common Shares 2) Cash in lieu of approximately 0.3333 fractional NXTC Shares

As of July 16, 2025, the NXTC Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a NXTC1 price for use in expiration processing, OCC will use the following formula:

NXTC1 = 0.083333 (NXTC)

For example, if NXTC closes at 4.76, the NXTC1 price would be:

NXTC1 = 0.083333 (4.76) = 0.40

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the reverse split.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com.

Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email <u>memberservices@theocc.com</u>.